Skip to Main Content

Paper Details

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
Nat Biotechnol
102
2022
ICB, cancer, patients, tumor
Author NameAffiliation
Mark LeeMemorial Sloan Kettering Cancer Center
Mark LeeMemorial Sloan Kettering Cancer Center
Daniel W KellyMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovMemorial Sloan Kettering Cancer Center
Vladimir MakarovCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Fengshen KuoMemorial Sloan Kettering Cancer Center
Fengshen KuoMemorial Sloan Kettering Cancer Center
Nadeem RiazMemorial Sloan Kettering Cancer Center
Nadeem RiazMemorial Sloan Kettering Cancer Center
Nadeem RiazMemorial Sloan Kettering Cancer Center
Marc LadanyiMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Mithat GonenMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Niels WeinholdMemorial Sloan Kettering Cancer Center
Niels WeinholdMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanWeill Cornell School of Medicine
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanWeill Cornell School of Medicine
  • 1 - 32

Datasets

Release 1.2